Table 1.
Form | PDB ID | TAFI Variant 1 | Ligand 2 | Resolution (A) | Ref. |
---|---|---|---|---|---|
TAFI | 3D66 | Human TAFI | - | 3.1 | [30] |
3D67 | Human TAFI | GEMSA | 3.4 | [30] | |
3D68 | Human TAFI-IIYQ | - | 2.8 | [30] | |
4P10 | Human TAFI | Compound 5 | 2.0 | [33] | |
3DGV | Bovine TAFI | - | 2.5 | - | |
3OSL | Bovine TAFI | TCI | 6.0 | [34] | |
5HVF | Human TAFI-CIIYQ | Nanobody VHH-i83 | 2.8 | [35] | |
5HVG | Human TAFI-CIIYQ | Nanobody VHH-a204 | 3.0 | [35] | |
5HVH | Human TAFI-CIIYQ | VHH-i83 + VHH-a204 | 3.0 | [35] | |
TAFIa | 3D4U | Bovine TAFIa | TCI | 2.5 | [36] |
3LMS | Human TAFIa | TCI | 1.7 | [32] | |
4UIA | Porcine TAFIa | Compound 3a | 2.2 | [37] | |
4UIB | Porcine TAFIa | Compound 3p | 1.9 | [37] | |
5LYF | Porcine TAFIa | Urea lead of compounds 1 and 6–7a | 2.0 | [38] | |
5LYD | Porcine TAFIa | Compound 1 | 2.0 | [38] | |
5LYI | Porcine TAFIa | Compound 7a | 1.6 | [38] | |
5LYL | Porcine TAFIa | Compound 6a | 1.8 | [38] |
1 TAFI-IIYQ: TAFI-T325I-T329I-H333Y-H335Q; TAFI-CIIYQ: TAFI-S305C-T325I-T329I-H333Y-H335Q. 2 GEMSA: (2-guanidinoethylmercapto)-succinic acid; TCI: tick carboxypeptidase inhibitor.